拉米夫定联合阿德福韦酯治疗乙型肝炎相关性肝癌的生存分析

摘要

Objective: To analyze the clinical factors predicting long-term survival after combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B .Method:The clini-cal data of 55 patients with hepatic carcinoma who underwent combination therapy of lamivudine with adefovir dipivoxil from 2009 to 2012 were analyzed Retrospectively .The patients were divided into antiviral group ( 30 cases treated with lamivudine with adefovir dipivoxil ) and non-antiviral group ( 25 cases without antivirus therapy ) .Both of two group were treated with resection of liver cancer or transcatheter arterial chemoemboli-zation.Result:The survival time of antiviral group was longer than non-antiviral group(P<0.05).Conclu-sion:Combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B can improve suvival time .%目的：探讨拉米夫定联合阿德福韦酯联合治疗对乙型肝炎相关性肝癌生存的影响。方法：回顾性分析2008年7月至2011年1月以来我院门诊及住院的55例HBV-DNA阳性的原发性肝癌患者，治疗组30例，对照组25例，两组均给予相同的针对肿瘤的治疗，治疗组应用拉米夫定联合阿德福韦酯抗病毒治疗，对照组不给于抗病毒治疗。采用log rank检验两组生存时间差异，用Kaplan-Meier绘制患者生存曲线。结果：治疗组患者生存时间高于对照组，两组差异有显著性（ P＜0．05）。结论：拉米夫定联合阿德福韦酯治疗乙肝相关性肝癌术后患者可以延长患者的生存期。